Pershing Square

Perishing Square's Bill Ackman has transcended the investing world and has now become fodder for Wall Street's favorite contrarian newsletter writer. On Wednesday, Dennis Gartman spared nearly one page of his eight-page note to address Ackman's Valeant Pharmaceuticals Intl Inc (NYSE:...

Major activist hedge funds have formed a lobbying group called Council for Investor Rights and Corporate Accountability (CIRCA) to promote shareholder activism across the country. The announcement comes as presidential candidates Hillary Clinton and Bernie Sanders have been voicing against activist...

It’s no secret that Bill Ackman has had a rough start to 2016. How rough? In his quarterly letter to investors, Ackman disclosed Pershing Square’s Q1 performance, and it’s not pretty. According to the letter, Ackman’s fund was down 25.6 percent in the first three months of...

A series of emails sent by Bill Ackman, including two to former Valeant Pharmaceuticals Intl Inc (NYSE: VRX) CEO Michael Pearson, were posted on Twitter by @piermont_morgan on Tuesday morning. The user seems to imply Ackman was asking for and discussing non-public earnings and guidance...

J C Penney Company Inc (NYSE: JCP) shares are poised to finish the week down more than 10 percent after the company announced it will be taking a series of drastic measures to help protect the struggling companies bottom line. The New York Post reported that JCPenney has slashed payroll, frozen...

Editor's note: A previous version of this story inaccurately stated Pershing added to its Valeant stake after selling a portion of its Mondelez stake. SEC filings indicate Pershing owned 9 percent of the company as of March 28, 2016, same as reported at the beginning of the year. It's...

Amid a sinking stock price and a flurry of downgrades, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has released some progressive news In a press release, Valeant announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay...

Bill Ackman and his Pershing Square hedge fund were both large winners throughout 2014. The same can't be said for 2015. According to Reuters, Ackman's Pershing Square fund lost between 16 to 20 percent in 2015. In fact, he even admitted to investors that he made several errors...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading higher by 2 percent early Friday morning. The stock is still lower by more than 50 percent over the past month. The New York Post reported that Bill Ackman hinted at a possible sale of the company. Shares of Valeant...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell 6 percent on Wednesday and remain within striking distance of its 52-week low of $88.50. Activist investor and Valeant shareholder Bill Ackman wrote a letter to Valeant's CEO saying his reputation is "at grave risk"...

The tale of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has gotten plenty of press in recent days. Even with Wednesday's nifty 11.9 percent surge (at this writing) on heavy volume, the drug maker's shares are still down about 18 percent over the past week and more than 23 percent over...

Pershing Square could be under an SEC investigation for alleged stock manipulation. The investigation may stem from the hedge fund's short thesis in Herbalife Ltd. (NYSE: HLF). Tim Ramey of Pivotal Research believes an SEC investigation began at some point between July 7 and September 15....